Login to Your Account



Armed and Helpful

Vascular-Targeting Agent Fights AML

By Anette Breindl
Science Editor

Friday, September 6, 2013
Mention “vasculature” and “cancer drug” in the same sentence, and most people with think anti-angiogenesis. Which, with blockbusters like Avastin (bevacizumab, Roche AG) on the market and dozens of angiogenesis inhibitors in development, is not surprising.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription